Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-07-27 Major Shareholding Noti…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissements de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing specifically reports changes in significant share ownership, where an entity crosses a predefined threshold (like 5% or 10%) of a company's capital or voting rights. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The text details the date and percentage of the crossing (e.g., crossing below 5% of capital and voting rights) by Amiral Gestion concerning NANOBIOTIX shares.
2021-07-27 French
Inside Information / News release on accounts, results
Earnings Release Classification · 95% confidence The document is a press release titled 'Nanobiotix Provides Second Quarter Operational and Financial Update'. It provides a summary of operational highlights, a brief overview of financial position (unaudited cash and revenue figures), and mentions future reporting dates. It does not constitute a full interim financial report (which would include comprehensive financial statements) but rather serves as an initial announcement of quarterly results and operational progress. Therefore, it is classified as an Earnings Release (ER). Q2 2021
2021-07-20 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and provides an update on the company's operational and financial situation for the second quarter (Q2 2021). It details key highlights, including clinical trial updates (ASCO presentation), a new strategic partnership (LianBio), management changes, and the cash position as of June 30, 2021. Crucially, it states: "La Société prévoit de publier ses résultats financiers pour le semestre arrêté au 30 juin 2021, incluant ses états financiers consolidés résumés pour la période, le 8 septembre 2021." This indicates the document itself is a summary/update, not the full, detailed financial report (which is scheduled for September 8th). The content focuses on key results and operational milestones for a specific period (Q2/H1), which aligns best with an Earnings Release (ER) or potentially an Interim Report (IR) if it contained full statements. Given the format is a press release summarizing key financial and operational metrics for the period, 'ER' (Earnings Release) is the most appropriate classification, as it precedes the full 'IR' or '10-K'. It is not a mere announcement of a report (RPA) because it contains substantial financial and operational data, not just a notice. Q2 2021
2021-07-20 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of June 30, 2021. This type of mandatory monthly disclosure regarding the total share capital and voting rights structure is a specific regulatory filing in France, often related to major shareholding notifications or capital structure transparency. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit as it deals with changes in significant share ownership levels/capital structure transparency, although it is specifically a monthly capital update. Given the content focuses purely on the count of shares and voting rights, it aligns best with the spirit of tracking ownership changes, which MRQ covers, or it could be considered a general regulatory filing (RNS). However, since it is a specific, recurring report on the capital structure, and not a general announcement, MRQ is a strong candidate if the definition is interpreted broadly to include capital structure updates that impact voting power thresholds. If we strictly adhere to the definitions, this is a specific disclosure about the capital base, which is often grouped with major shareholding reports. Let's re-evaluate the options: It is not an ER, IR, 10-K, or AR. It is not a DIRS (director dealing). It is a mandatory disclosure about the total number of shares/votes. This is a common requirement that often accompanies or precedes major shareholding reports. Given the options, 'MRQ' (Major Shareholding Notification) is the most appropriate category for mandatory disclosures tracking the total voting rights/share count, as these figures are crucial for determining when ownership thresholds are crossed. If MRQ is strictly for *changes* crossing thresholds, and this is a static monthly report, 'RNS' (Regulatory Filings) might be the fallback. However, in many contexts, these monthly capital structure reports are filed under the same umbrella as major holding reports. Given the highly specific nature of the data (total shares/votes), MRQ is a better fit than the generic RNS.
2021-07-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is explicitly titled "*PRESS RELEASE*" and announces a specific corporate event: the initiation of a new clinical study evaluating NBTXR3 in lung cancer. It contains key highlights, quotes from the CEO, and details about the study design and collaboration milestones. This format—a brief, timely announcement of a significant operational update (clinical trial initiation)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release detailing operational progress rather than a full financial report (10-K, IR) or a formal regulatory filing notification (RPA/RNS), and it focuses on key operational news, the most fitting category is Earnings Release (ER), which often encompasses major operational updates released outside of formal quarterly filings. However, given the content is purely clinical/operational news and not financial results, it fits better under a general announcement category. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is not financial results, we must re-evaluate. This is a press release announcing a clinical development milestone. This type of announcement, which is not a formal financial report, dividend notice, or management change, often falls under the general 'Regulatory Filings' (RNS) category if no other specific category applies. Given the options, and recognizing this is a standard corporate announcement of a clinical trial start, RNS (Regulatory Filings/General Regulatory Announcements) is the most appropriate fallback, as it is not a CT, IP, or ER (which focuses on financials).
2021-06-30 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a specific corporate/scientific event: the launch of a new clinical study evaluating NBTXR3 in lung cancer. It provides details about the study design (Phase I, dose cohorts), collaboration with MD Anderson, and future development plans. This type of announcement, focusing on operational progress, clinical trial initiation, and scientific updates, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a specific financial disclosure (like DIV or CAP). Since it is a press release detailing operational progress and clinical milestones, it fits best under the general Regulatory Filings category (RNS) as a non-standard, material announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate catch-all for significant, non-standard corporate news releases that aren't earnings or management changes. However, since it details significant operational progress (clinical trial launch), it is a material announcement. Given the options, RNS (Regulatory Filings/General Announcement) is the best fit for a press release detailing clinical trial progress when a more specific category like 'IP' (Investor Presentation) or 'ER' (Earnings Release) does not apply.
2021-06-30 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.